Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.
Alexion developed Soliris® (eculizumab) from the laboratory through commercialization for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two life-threatening, ultra-rare disorders. Today, Soliris is approved in more than 50 countries for PNH and more than 40 countries for aHUS. Download Soliris prescribing information (PDF).
As we continue to expand our operations into additional countries, Alexion is advancing the most robust rare disease pipeline in the biotech industry. With highly innovative product candidates in multiple therapeutic areas, Alexion has emerged as one of the world's leading rare disease companies. The Company is establishing a premier global metabolic rare disease franchise which includes Strensiq™ (asfotase alfa) for patients with hypophosphatasia (HPP) and Kanuma™ (sebelipase alfa) for patients with lysosomal acid lipase deficiency (LAL Deficiency, or LAL-D). Strensiq is approved in the United States, European Union, Japan and Canada, and Kanuma is approved in the European Union. In addition, as the global leader in complement inhibition, we are strengthening and broadening our portfolio of complement inhibitors across diverse platforms, including evaluating potential indications for Soliris in additional severe and ultra-rare disorders.
Alexion was established in the U.S. in 1992 and became a public company in 1996 (NASDAQ: ALXN). We were added to the NASDAQ-100 Index in 2011 and to the Standard & Poor's 500 Index in 2012.
Our global headquarters and research operations are in Cheshire, Conn., and will move to New Haven, Conn. in early 2016. Alexion's approximately 3,000 employees around the world serve patients in 50 countries.